Advertisement
Research Article

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

  • Eduardo Díaz-Rubio mail,

    ediazrubio.hcsc@salud.madrid.org

    Affiliation: Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

    X
  • Auxiliadora Gómez-España,

    Affiliation: Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain

    X
  • Bartomeu Massutí,

    Affiliation: Department of Medical Oncology, Hospital General, Alicante, Spain

    X
  • Javier Sastre,

    Affiliation: Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

    X
  • Margarita Reboredo,

    Affiliation: Department of Medical Oncology, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain

    X
  • José Luis Manzano,

    Affiliation: Department of Medical Oncology, Instituto Catalán de Oncología, Hospital Germans Trias I Pujol, Badalona, Spain

    X
  • Fernando Rivera,

    Affiliation: Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain

    X
  • MªJosé Safont,

    Affiliation: Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain

    X
  • Clara Montagut,

    Affiliation: Department of Medical Oncology, Hospital del Mar, Barcelona, Spain

    X
  • Encarnación González,

    Affiliation: Department of Medical Oncology, Hospital Virgen de las Nieves, Granada, Spain

    X
  • Manuel Benavides,

    Affiliation: Department of Medical Oncology, Hospital Universitario Carlos Haya, Málaga, Spain

    X
  • Eugenio Marcuello,

    Affiliation: Department of Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

    X
  • Andrés Cervantes,

    Affiliation: Department of Medical Oncology, Institute of Health Research INCLIVA. University of Valencia, Valencia, Spain

    X
  • Purificación Martínez de Prado,

    Affiliation: Department of Medical Oncology, Hospital de Basurto, Vizcaya, Spain

    X
  • Carlos Fernández-Martos,

    Affiliation: Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain

    X
  • Antonio Arrivi,

    Affiliation: Department of Medical Oncology, Fundación Hospital Son Llatzer, Palma de Mallorca, Spain

    X
  • Inmaculada Bando,

    Affiliation: Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

    X
  • Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD),

    Affiliation: Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain

    X
  • E. Aranda

    Membership of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) is provided in the Acknowledgments

    X
  • Published: October 12, 2012
  • DOI: 10.1371/journal.pone.0047345

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.